For Health Care Practitioners · Canada
Quercetin and pollen extract, two of the phytotherapies named in the 2025 AUA guideline for CP/CPPS, in one Health Canada-licensed tablet
Pro-UROL (NPN 80147704) is licensed to help relieve the pain of non-bacterial chronic prostatitis. It is made in Canada. This page gives you the monograph, the trial data with its limits, and a one-page handout for your patients.
CP/CPPS: a common condition with few reliable answers
Chronic prostatitis/chronic pelvic pain syndrome (NIH Category III) affects about 8% of adult men in pooled population studies (range 2.2–9.7%, depending on case definition). Category II chronic bacterial prostatitis accounts for fewer than 10% of chronic prostatitis presentations, which is why empiric antibiotics so often fail: six weeks of levofloxacin (Nickel 2003) and of ciprofloxacin, tamsulosin or both (Alexander 2004) did not meaningfully outperform placebo on the NIH-CPSI.
Because the syndrome is heterogeneous, care is increasingly matched to the six UPOINT domains (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness). In a prospective cohort of 100 men treated by phenotype, 84% achieved a ≥6-point NIH-CPSI decrease (Shoskes 2010). Quercetin and pollen extract are typically assigned to the Organ-specific domain. Pro-UROL is designed as that Organ-specific component, not as a substitute for diagnosis or phenotype-directed care.
Product monograph
Download the full practitioner monograph (PDF, 6 pages): CP/CPPS background, product information, AUA 2025 and CUA 2011 recommendation tables, trial data, Cochrane effect sizes, safety and monitoring.
| Product name | Pro-UROL |
| NPN | 80147704 (licensed 6 March 2026, active) |
| Licence holder | Aleaf Labs Inc., Markham, Ontario |
| Dosage form | Tablet, oral |
| Medicinal ingredients (per tablet) | Quercetin 400 mg (quercetin dihydrate, synthetic) Pollen extract 120 mg (Secale cereale pollen; 10:1, equivalent to 1,200 mg dried) Papain 50 mg (Carica papaya fruit; 100,000 FCC PU) Stem bromelain 33.33 mg (Ananas comosus var. bracteatus stem; 1,200,000 FCC PU) |
| Non-medicinal ingredients | Microcrystalline cellulose, dicalcium phosphate, croscarmellose sodium, magnesium stearate, silicon dioxide, polyvinyl alcohol, polyethylene glycol (macrogol), talc |
| Recommended use | "Source of/Provides antioxidants. Helps to support prostate health. Helps relieve the pain of non-bacterial chronic Prostatitis. Helps relieve pain associated with chronic prostatitis to support quality of life." |
| Dose | Men 18 years and older: 1 tablet TID, taken with food (with meals, which also makes the three daily doses easy to remember). |
| Daily totals | Quercetin 1,200 mg; pollen extract 360 mg (3,600 mg pollen equivalent); papain 150 mg; stem bromelain 100 mg |
| Duration of use | Consult a health care practitioner for use beyond 12 weeks. |
| Pack | 90 tablets (30-day supply) |
| Storage | 15–30 °C, away from light and moisture. Do not use if seal is broken. |
| Manufacture | Made in Canada in a GMP-certified facility, from domestic and imported ingredients. Non-GMO; Halal. |
Verify against the Health Canada LNHPD record for NPN 80147704.
Cautions, contraindications and interactions
Contraindication (licensed): Do not use in patients allergic to bee products or pollen.
Cautions (licensed): Consult before use in patients who take a blood thinner, anti-inflammatory drugs or antibiotics; have a stomach or intestinal ulcer or lesion; are having surgery; or are allergic to latex or certain fruits (avocado, banana, chestnut, passion fruit, fig, melon, mango, kiwi, pineapple, peach, tomato).
Additional considerations from the ingredient literature
- Anticoagulants and antiplatelets. Bromelain and papain may add to bleeding risk. A case report associated quercetin with a raised INR on warfarin. Consider monitoring, and stopping before elective surgery.
- Drug metabolism. Quercetin modulates CYP3A4 and P-glycoprotein in vitro; clinical significance is uncertain. Review narrow-therapeutic-index medicines.
- Fluoroquinolones. In vitro data suggest quercetin may interfere with fluoroquinolone activity. A comparable Canadian product carries a licensed caution; Pro-UROL's licence does not, but separating doses or avoiding concurrent use is prudent.
- Renal impairment. Nephrotoxicity has been reported with high-dose intravenous quercetin, not oral use. Use judgment in significant renal disease.
- Tolerability. Oral quercetin up to 1,000 mg/day for 12 weeks is generally well tolerated. Mild gastrointestinal upset has been reported with pollen extract.
What the trials show, and what they don't
| Ingredient | Pro-UROL per day | CP/CPPS trial | Limitations |
|---|---|---|---|
| Quercetin | 1,200 mg | Shoskes 1999: RCT, n=30, 500 mg BID for 4 weeks. NIH-CPSI 21.0 → 13.1 vs 20.2 → 18.8 on placebo; ≥25% improvement in 67% vs 20%. | Small, single-centre, short; not replicated at scale. |
| Pollen extract | 360 mg (10:1) | Wagenlehner 2009: RCT, n=139, inflammatory CP/CPPS (IIIA), Cernilton ~378 mg/day for 12 weeks. Responders 70.6% vs 50.0% on placebo. | Trial used Cernilton, a standardized rye-grass pollen extract; extracts may differ. IIIA only. |
| Stem bromelain | 100 mg | None | Proposed to aid quercetin absorption; unproven. Adds bleeding and allergy considerations. |
| Papain | 150 mg | None | As above; latex-fruit cross-reactivity. |
Supporting data: an open-label extension of the 1999 trial (n=17) reported a 25% or greater improvement in 82% of men taking a quercetin-bromelain-papain combination; no control group. A Cochrane review of seven phytotherapy trials found a mean NIH-CPSI reduction of about 5 points versus placebo (low-certainty evidence).
Where the guidelines place phytotherapy
- AUA 2025 (Male Chronic Pelvic Pain): clinicians "may prescribe phytotherapeutics including saw palmetto, quercetin, and pollen extract to improve pain, voiding symptoms, and quality of life" (Conditional Recommendation; Evidence Level Grade B). The guideline names ingredients, not brands.
- CUA 2011 (Prostatitis): quercetin and cernilton listed as options, likely most useful within individualized multimodal therapy.
- Neither guideline places phytotherapy ahead of alpha-blockers for voiding symptoms, pelvic floor physiotherapy, or low-intensity shockwave therapy.
Where it fits in a treatment plan
Patient selection
- Men with CP/CPPS (NIH Category III) after infection, STI and other causes have been excluded.
- Best positioned as one component of multimodal, phenotype-directed care (UPOINT), not as monotherapy for severe or refractory disease.
- Not indicated for bacterial prostatitis, BPH or prostate cancer.
Measuring response
Record a baseline NIH-CPSI and repeat at about 12 weeks. A reduction of about 6 points is the established threshold for a clinically perceptible change. Stop if there is no meaningful response. Patients can self-score with our free NIH-CPSI calculator, and the patient handout includes a tracking table.
Patients with a history of pelvic radiation
Pro-UROL is licensed for non-bacterial chronic prostatitis only; it is not licensed for, and has not been studied in, radiation-related urinary or pelvic symptoms. A trial of a similar quercetin-based product after prostate brachytherapy is registered (ClinicalTrials.gov NCT04252625); we are not aware of published results. Quercetin is an antioxidant, and its use during active radiotherapy has not been studied. Timing relative to treatment is a matter for the treating team's judgment.
Why we made Pro-UROL
We kept seeing men with CP/CPPS go without, because every comparable formula in Canada was on backorder. A patient who has found something that helps, and then cannot get it, is back where he started.
So we developed Pro-UROL with physicians and botanists around the same ingredient types, and had it made in Canada, in a GMP-certified facility, so Canadian patients can count on a steady supply.
Resources for your patients
One page: licensed uses, dosing, cautions, red flags, a 12-week NIH-CPSI tracker and space for your name and follow-up.
Download and print →Free online version of the questionnaire, scored automatically. Short link for patients: aleaflabs.com/cpsi
Open the calculator →Plain-language guide to diagnosis, differentials, red flags and guideline-based treatment options.
Read the guide →Patient-facing summary of what the evidence for Pro-UROL does and does not show.
Read the review →Want printed copies for your waiting room? Request a free clinic pack.
Get a free clinic pack
We will mail your clinic printed patient handouts and a printed copy of this monograph, free. An Aleaf Labs authorized representative will also call you, usually within two business days, to answer questions about the formula, interactions or supply.
References
- Health Canada. Licensed Natural Health Products Database: Pro-UROL, NPN 80147704. LNHPD record
- Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54(6):960-3. PubMed
- Wagenlehner FME, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009;56(3):544-51. PubMed
- Lai HH, Pontari MA, et al. Diagnosis and Management of Male Chronic Pelvic Pain: AUA Guideline. J Urol 2025;214(2):127-37. AUA
- Nickel JC. Prostatitis. Can Urol Assoc J 2011;5(5):306-15. CUA guideline (PDF)
- Franco JVA, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2019; CD012552. PubMed
- Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health Chronic Prostatitis Symptom Index. J Urol 1999;162(2):369-75. PubMed
- Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the NIH Chronic Prostatitis Symptom Index. Qual Life Res 2006;15(2):299-305. PubMed
- Memorial Sloan Kettering Cancer Center. About Herbs: Quercetin. MSKCC
- ClinicalTrials.gov. NCT04252625. Registry record
- Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008;31 Suppl 1:S85-90.
- Nickel JC, Downey J, Clark J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003;62(4):614-7.
- Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141(8):581-9.
- Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010;75(6):1249-53.